TriSalus Life Sciences (NASDAQ:TLSI) Given New $10.00 Price Target at HC Wainwright

Posted by Geri Gentry on Nov 12th, 2026

TriSalus Life Sciences (NASDAQ:TLSI – Free Report) had its price target lowered by HC Wainwright from $12.00 to $10.00 in a research note issued to investors on Wednesday,Benzinga reports. The brokerage currently has a buy rating on the stock.

Several other equities analysts have also commented on the stock. Guggenheim set a $12.00 target price on shares of TriSalus Life Sciences in a report on Wednesday, September 23rd. Stifel Nicolaus set a $12.00 price target on shares of TriSalus Life Sciences in a report on Wednesday, September 23rd. Wall Street Zen downgraded shares of TriSalus Life Sciences from a “hold” rating to a “sell” rating in a report on Saturday, November 7th. Zacks Research upgraded shares of TriSalus Life Sciences to a “hold” rating in a research report on Thursday, September 10th. Finally, Canaccord Genuity Group decreased their price objective on shares of TriSalus Life Sciences from $7.00 to $4.00 and set a “buy” rating on the stock in a research note on Tuesday. Four analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $9.20.

Check Out Our Latest Stock Report on TLSI

TriSalus Life Sciences Stock Down 19.3%

Shares of NASDAQ TLSI opened at $2.30 on Wednesday. The stock has a market capitalization of $141.63 million, a P/E ratio of -4.69 and a beta of 0.50. The stock’s fifty day moving average is $4.15 and its 200 day moving average is $4.32. TriSalus Life Sciences has a 52 week low of $2.20 and a 52 week high of $7.95. The company has a debt-to-equity ratio of 5.05, a quick ratio of 4.97 and a current ratio of 5.35.

TriSalus Life Sciences (NASDAQ:TLSI – Get Free Report) last posted its quarterly earnings data on Tuesday, November 10th. The company reported ($0.15) earnings per share for the quarter, missing the consensus estimate of ($0.13) by ($0.02). The company had revenue of $12.88 million for the quarter, compared to analyst estimates of $14.02 million. Sell-side analysts forecast that TriSalus Life Sciences will post -0.53 earnings per share for the current fiscal year.

Institutional Trading of TriSalus Life Sciences

Several institutional investors and hedge funds have recently modified their holdings of TLSI. White Pine Capital LLC bought a new position in TriSalus Life Sciences in the third quarter valued at about $2,143,000. Royce & Associates LP acquired a new position in TriSalus Life Sciences during the third quarter worth about $862,000. Russell Investments Group Ltd. bought a new position in shares of TriSalus Life Sciences in the third quarter worth about $68,000. Provenance Wealth Advisors LLC bought a new position in shares of TriSalus Life Sciences in the third quarter worth about $94,000. Finally, CWA Asset Management Group LLC bought a new position in shares of TriSalus Life Sciences in the third quarter worth about $310,000. 2.58% of the stock is currently owned by institutional investors.

More TriSalus Life Sciences News

Here’s some of the latest news about TLSI:

Positive Sentiment: TriSalus reported Q3 revenue growth of 11.3% year over year, to approximately $12.9 million. The company also highlighted TriNav Advance clearance as a potential support for growth in 2027. Article: TriSalus outlines 2026 outlook and 2027 growth drivers
Positive Sentiment: The company raised its FY2026 revenue outlook to $46 million–$48 million, according to the report. However, that range remains below analyst consensus. Article: TriSalus reports Q3 revenue growth and FY2026 outlook
Negative Sentiment: HC Wainwright cut its price target to $10 from $12, although it maintained a Buy rating. Article: HC Wainwright stock recommendations

About TriSalus Life Sciences

(Get Free Report)

TriSalus Life Sciences is a medical technology and oncology company developing ways to improve the delivery of treatments to solid tumors. Its Pressure-Enabled Drug Delivery (PEDD) platform is designed to increase the distribution of therapeutic agents within tumor tissue by using controlled pressure during infusion. The company’s TriNav® infusion system is designed to deliver therapies to the liver through the hepatic artery. TriSalus is also developing PEDD-based approaches for liver and pancreatic tumors, including use with its investigational immunotherapy SD-101, a toll-like receptor 9 agonist.